REGENXBIO Completes Dosing In Its Confirmatory Study Of RGX-202 Gene Therapy For Duchenne Muscular Dystrophy

Benzinga Newsdesk www.benzinga.com Positive 88.3%

Neg 0% Neu 0% Pos 88.3%

Confirmatory study completed ahead of schedule due to strong patient demand and robust investigator interest
On track to initiate BLA in Q3 2026 under the accelerated approval pathway supporting potential approval in 2H 2027

Comments

No comments yet. Be the first!